Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
11/01/2022 - 07:30 AM
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after market close on Tuesday, November 8th, 2022. Starting at 5:00 p.m. Eastern Time on November 8, 2022, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. The press release with the third quarter 2022 financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call.
A replay of the webcast will be available on http://investors.coherus.com following the conclusion of the live conference call.
Conference Call Information When: Tuesday, November 8th, 2022, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the following link to receive dial-in information and personal PIN to access the live call: https://register.vevent.com/register/BI79684ca1b45c46df988c8f9aac6f09af
Webcast: https://investors.coherus.com/upcoming-events
Please dial-in 15 minutes early to ensure a timely connection to the call.
Coherus Contact Information: Marek Ciszewski, SVP Investor Relations Coherus Biosciences, Inc.IR@coherus.com
CHRS Rankings
#5124 Ranked by Stock Gains
CHRS Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Redwood City
About CHRS
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp